Chengdu Kanghong Pharmaceutical Group (002773.SZ): KHN707 tablets approved for clinical trials for insomnia.
Kanghong Pharmaceutical (002773.SZ) announced that the company has received the "Notice of Drug Clinical Trial Approval" issued by the National Medical Products Administration. The related drug is KHN707 tablets, which will be used for clinical trials in the treatment of insomnia.
Chengdu Kanghong Pharmaceutical Group (002773.SZ) announced that the company has received the "Notification of Drug Clinical Trial Approval" issued by the National Medical Products Administration. The related drug is KHN707 tablets, and it will be used for clinical trials for insomnia.
Related Articles
On February 25, XD INC (02400) spent 4.8488 million Hong Kong dollars to repurchase 63,000 shares.
HuaDian Heavy Industries (601226.SH) won a bid for a related EPC project worth 827 million yuan.
Wens Foodstuff Group (300498.SZ) plans to spend 800 million to 1.2 billion yuan to implement the repurchase of A shares.
On February 25, XD INC (02400) spent 4.8488 million Hong Kong dollars to repurchase 63,000 shares.
HuaDian Heavy Industries (601226.SH) won a bid for a related EPC project worth 827 million yuan.
Wens Foodstuff Group (300498.SZ) plans to spend 800 million to 1.2 billion yuan to implement the repurchase of A shares.
RECOMMEND
Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026
Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026
AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026
